Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor
(RTTNews) - Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.
This clearance builds on Abbott's portfolio of connected health devices that can better help doctors manage and treat their patients remotely.
Using Bluetooth technology, Abbott's Assert-IQ ICM is designed to remain connected to a transmitter - usually the person's own cell phone - where it checks heart rhythms every 20 seconds, transmitting results in real-time to the clinic's portal.
The Assert-IQ ICM also offers advanced diagnostic capabilities to provide physicians with more clinically relevant information about the cardiovascular health of the patient, allowing care providers to make clinical decisions faster.
Abbott Q2 Profit Plunges, Lifts FY26 Adj. EPS View, Backs Sales Forecast; Stock Up 11%
Abbott Laboratories Boosts FY24 Earnings Outlook - Update
Abbott Says FDA Approves First-of-Its-Kind TriClip Transcatheter Edge-to-edge Repair System
Abbott Laboratories Guides FY24 Adj. EPS In Line With Estimates - Update
Abbott Inks Deal With MAbxience To Commercialize Biosimilar Molecules In Emerging Markets
Abbott Laboratories Reaffirms FY23 Adj. EPS Outlook - Update
Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain
